Fig. 6: Suppressive effects of DCAF1 and EZH2 inhibitors against patient-derived tumor organoids.
a PDOs were treated with B32B3 and/or Taz at indicated concentrations and analyzed by CellTiter-Glo (CTG) 3D luminescent cell viability assay as recently described6. Shown are the dose-response curves depicting the relative luminescence units for each treatment condition represented with mean ± SEM (n = 3) from one representative CTG assay on PDO-000V8 with n = 6 technical replicates. P values were calculated using student one-sided t-tests. ***P < 0.001 versus DMSO; ###P < 0.001 versus B32B3 (5 µM). b Brightfield images of PDOs were captured at day 0 and day 5 after treatment with B32B3 (5 µM) and/or Taz (50 µM) as indicated, and processed with a high-content analysis system. A representative organoid from day 5 post-treatment has been magnified within each field. Orange scale bars = 200 µm. c Box plot displays the counts of PDOs in (b). The central line in the box represents the median, and the edges of the boxes are the 25% and 75% percentile, respectively. The whiskers represent the extent of the data within 1.5 times the interquartile range. P values were calculated using one-way ANOVA with post-hoc Tukey’s test for multiple comparisons. ***P < 0.001 versus DMSO; †††P < 0.001 versus Taz; ###P < 0.001 versus B32B3. d Violin plot represents the distribution of the size of a single PDOs in (B). P values were calculated using one-way ANOVA with post-hoc Tukey’s test for multiple comparisons. **p < 0.01and ***P < 0.001 versus DMSO; #P < 0.05. (a, c and d) Source data are provided as a Source Data file.
